<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39360875</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-2995</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>03</Day></PubDate></JournalIssue><Title>Transfusion</Title><ISOAbbreviation>Transfusion</ISOAbbreviation></Journal><ArticleTitle>Parvovirus B19 rebound outbreak 2024 and implications for blood- and plasma-product safety.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/trf.18032</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Since the beginning of 2024, several European countries reported unusually high numbers of Human parvovirus B19 (B19V) infections. An increase in B19V incidence rate might have implications for blood products for direct transfusion, however, large data sets for analysis of this outbreak are missing.</AbstractText><AbstractText Label="STUDY DESIGN AND METHODS" NlmCategory="METHODS">B19V nucleic acid testing (NAT) of plasma donations collected between June 2018 and May 2024 from mainly Central European countries (n = 9.6 million) and the United States (n = 70.7 million) was done to the individual donation level.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In Central Europe, there was a marked increase in B19V incidence from November 2023 onwards, which peaked in April 2024 with a 33-fold higher than average B19V incidence versus before the COVID-19 pandemic. In the United States, a similar trend was seen, with a yet still 6-fold lower increase than in Europe at the same time. The largest increase in B19V positivity was seen in the youngest plasma donor cohort.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">A B19V infection gap during the COVID-19 pandemic is likely the basis for the rebound outbreak in 2023/2024, particularly in Europe. B19V NAT of millions of plasma donations provides for large scale numbers to solidify available epidemiology insight, and to support adequate risk assessments. Based on the situation it may be prudent to consider B19V NAT for blood components specifically directed towards transfusion to higher risk recipients, or alternatively, preselecting B19V seropositive individuals or advanced age donors at higher likelihood of seropositivity and thus lower risk of virus transmission.</AbstractText><CopyrightInformation>© 2024 The Author(s). Transfusion published by Wiley Periodicals LLC on behalf of AABB.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Farcet</LastName><ForeName>Maria R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-2335-8609</Identifier><AffiliationInfo><Affiliation>Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karbiener</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8064-2489</Identifier><AffiliationInfo><Affiliation>Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aberham</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biolife, Takeda Manufacturing Austria AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powers</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biolife Plasma Services, Takeda, Social Circle, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aue</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biolife, Takeda Manufacturing Austria AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreil</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials><Identifier Source="ORCID">0000-0001-9970-0987</Identifier><AffiliationInfo><Affiliation>Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transfusion</MedlineTA><NlmUniqueID>0417360</NlmUniqueID><ISSNLinking>0041-1132</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B19V epidemiology</Keyword><Keyword MajorTopicYN="N">parvovirus B19 outbreak</Keyword><Keyword MajorTopicYN="N">re‐emergence</Keyword><Keyword MajorTopicYN="N">risk assessment</Keyword><Keyword MajorTopicYN="N">transfusion transmission</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>9</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39360875</ArticleId><ArticleId IdType="doi">10.1111/trf.18032</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>European Centre for Disease Prevention and Control. Risks posed by reported increased circulation of human parvovirus B19 in the EU/EEA. ECDC: Stockholm (accessed September 2, 2024). 2024. https://www.ecdc.europa.eu/en/publications‐data/risks‐posed‐reported‐increased‐circulation‐human‐parvovirus‐b19‐eueea</Citation></Reference><Reference><Citation>Plasma Protein Therapeutics Association (PPTA). QSEAL NAT Testing Standard, v2.0 (Accessed September 02, 2024). https://cdn.prod.website‐files.com/638f893112c6eac0e46ac576/64517906a60bdb04ed8c3b74_NATTestingV2‐3.pdf</Citation></Reference><Reference><Citation>World Health Organization. Coronavirus disease (COVID‐19) pandemic (Accessed September 02, 2024). https://www.who.int/europe/emergencies/situations/covid-19</Citation></Reference><Reference><Citation>Wong S, Brown KE. Development of an improved method of detection of infectious parvovirus B19. J Clin Virol. 2006;3:407–413. https://doi.org/10.1016/j.jcv.2005.12.008</Citation></Reference><Reference><Citation>Guillet M, Bas A, Lacoste M, Ricard C, Visse C, Barlet V, et al. New atypical epidemiological profile of parvovirus B19 revealed by molecular screening of blood donations, France, winter 2023/24. Euro Surveill. 2024;29:2400253 https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2024.29.21.2400253</Citation></Reference><Reference><Citation>Heegaard E, Brown KE. Human parvovirus B19. Clin Microbiol Rev. 2002;15:482–505. https://doi.org/10.1128/CMR.15.3.485-505.2002</Citation></Reference><Reference><Citation>Groeneveld K, van der Noordaa J. Blood products and parvovirus B19. Neth J Med. 2003;61:154–156.</Citation></Reference><Reference><Citation>Roth NJ, Dichtelmüller HO, Fabbrizzi F, Flechsig E, Gröner A, Gustafson M, et al. Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 years' experience of the plasma protein manufacturers. Transfusion. 2020;60:2661–2674. https://doi.org/10.1111/trf.16022</Citation></Reference><Reference><Citation>Blümel J, Burger R, Drosten C, Groner A, Gurtler L, Heiden M, et al. Parvovirus B19 – revised: Arbeitskreis Blut, Untergruppe ‘Bewertung blutassoziierter Krankheitserreger’. Transfus Med Hemother. 2010;37:339–350. https://doi.org/10.1159/000322190</Citation></Reference><Reference><Citation>Berting A, Modrof J, Unger U, Gessner M, Klotz A, Pölsler G, et al. Inactivation of parvovirus B19 during STIM‐4 vapor heat treatment of three coagulation factor concentrates. Transfusion. 2008;48:1220–1226. https://doi.org/10.1111/j.1537-2995.2008.01662.x</Citation></Reference><Reference><Citation>Sun P, Jiang P, Liu Q, Zhang R, Wang Z, Cao H, et al. Parvovirus B19 DNA and antibodies in Chinese plasma donors, plasma pools and plasma derivatives. PeerJ. 2023;11:e15698. https://doi.org/10.7717/peerj.15698</Citation></Reference><Reference><Citation>Modrof J, Berting A, Tille B, Klotz A, Forstner C, Rieger S, et al. Neutralization of human parvovirus B19 by plasma and intravenous immunoglobulins. Transfusion. 2008;48:178–186. https://doi.org/10.1111/j.1537-2995.2007.01503.x</Citation></Reference><Reference><Citation>Aronson AT, Celiker MY, Guarini L, Agha R. Intravenous immunoglobulin treatment of congenital parvovirus B19 induced anemia – a case report. Matern Health Neonatol Perinatol. 2023;9:10. https://doi.org/10.1186/s40748‐023‐00164‐2</Citation></Reference><Reference><Citation>Kerr JR, Cunniffe VS, Kelleher P, Bernstein RM, Bruce IN. Successful intravenous immunoglobulin therapy in 3 cases of parvovirus B19‐associated chronic fatigue syndrome. Clin Infect Dis. 2003;36:e100–e106. https://doi.org/10.1086/374666</Citation></Reference><Reference><Citation>Crabol Y, Terrier B, Rozenberg F, Pestre V, Legendre C, Hermine O, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis. 2013;56:968–977. https://doi.org/10.1093/cid/cis1046</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>